Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)

14. juli 2026 oppdatert av: Yu Bo, Harbin Medical University

Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis: a Prospective, Multicenter, Open-label, Non-inferiority, Randomised Controlled Trial(EROSION IV)

This study is a prospective, multicenter, open-label, non-inferiority, randomized controlled trial. A total of 2,000 patients with STEMI (<24 hours or 7-14 days) or NSTEMI will be recruited from at least 20 centers in China. Eligible patients must have residual DS < 70% at the culprit lesion assessed by QCA, with optional thrombus aspiration, and TIMI flow of grade 3. Patients will be randomly assigned in a 1:1 ratio to the experimental group or the control group. The planned enrollment period is 36 months, and all patients will be followed up for at least 12 months after randomization, with continued follow-up until the end of the study. The primary outcome is the first occurrence of TLF after randomization, defined as the composite of cardiovascular death, target vessel myocardial infarction, ischemia-driven target lesion revascularization. The study aims to verify whether guideline-recommended standard medical therapy is non-inferior to DES implantation combined with guideline-recommended standard medical therapy in AMI patients with non-severe coronary artery stenosis.

A total of 120 participants (60 in the experimental group and 60 in the control group) enrolled at the Second Affiliated Hospital of Harbin Medical University were included in the functional substudy. Using Abbott Pressure Wire™X pressure wire test functional indicators, and explore the incidence of coronary microvascular dysfunction (CMD) as assessed by the index of microcirculatory resistance (IMR) in two groups, and its impact on the rate of the composite endpoint of all-cause death and heart failure readmission occurring for the first time within 12 months.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

2000

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

  • Kina
      • Beijing, Kina
        • Har ikke rekruttert ennå
        • Fuwai Hospital, Chinese Academy of Medical Sciences
        • Ta kontakt med:
          • Lei Song
      • Beijing, Kina
        • Har ikke rekruttert ennå
        • Beijing Luhe Hospital Affiliated to Capital Medical University
        • Ta kontakt med:
          • Guangyao Zhai
      • Cangzhou, Kina
        • Har ikke rekruttert ennå
        • Cangzhou Central Hospital
        • Ta kontakt med:
          • Jun Zhang
      • Chengde, Kina
        • Har ikke rekruttert ennå
        • Chengde Medical College Affiliated Hospital
        • Ta kontakt med:
          • Ying Zhang
      • Chengdu, Kina
        • Har ikke rekruttert ennå
        • Sichuan Provincial People's Hospital
        • Ta kontakt med:
          • Wenjie Tian
      • Dalian, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Dalian Medical University
        • Ta kontakt med:
          • Bo Zhang
      • Dalian, Kina
        • Har ikke rekruttert ennå
        • The Second Affiliated Hospital of Dalian Medical University
        • Ta kontakt med:
          • Xin Zhao
      • Dalian, Kina
        • Har ikke rekruttert ennå
        • The Central Hospital Affiliated to Dalian University of Technology
        • Ta kontakt med:
          • Xiaoqun Zheng
      • Daqing, Kina
        • Har ikke rekruttert ennå
        • Daqing Oilfield General Hospital
        • Ta kontakt med:
          • Zhiqi Sun
      • Harbin, Kina
        • Har ikke rekruttert ennå
        • The Fourth Affiliated Hospital of Harbin Medical University
        • Ta kontakt med:
          • Wei Yang
      • Hunan, Kina
        • Har ikke rekruttert ennå
        • The Third XIANGYA Hospital of Central South University
        • Ta kontakt med:
          • Yu Cao
      • Jiamusi, Kina
        • Har ikke rekruttert ennå
        • Central Hospital of Jiamusi City
        • Ta kontakt med:
          • Zhiyuan Weng
      • Jiamusi, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Jiamusi University
        • Ta kontakt med:
          • Guangyuan Yang
      • Jilin City, Kina
        • Har ikke rekruttert ennå
        • China-Japan Union Hospital of Jilin University
        • Ta kontakt med:
          • Yuquan He
      • Jilin City, Kina
        • Har ikke rekruttert ennå
        • Jilin Central Hospital
        • Ta kontakt med:
          • Yijun Shang
      • Jilin City, Kina
        • Har ikke rekruttert ennå
        • The First Hospital of Jilin University
        • Ta kontakt med:
          • Qian Tong
      • Jinan, Kina
        • Har ikke rekruttert ennå
        • Shandong Provincial Hospital
        • Ta kontakt med:
          • Haitao Yuan
      • Jining, Kina
        • Har ikke rekruttert ennå
        • The Affiliated Hospital of Jining Medical University
        • Ta kontakt med:
          • Lijun Gan
      • Lanzhou, Kina
        • Har ikke rekruttert ennå
        • Lanzhou University First Hospital
        • Ta kontakt med:
          • Ming Bai
      • Linyi, Kina
        • Har ikke rekruttert ennå
        • Linyi People's Hospital
        • Ta kontakt med:
          • Yanjin Wei
      • Mudanjiang, Kina
        • Har ikke rekruttert ennå
        • Mudanjiang Cardiovascular Hospital
        • Ta kontakt med:
          • Kai Liu
      • Nanyang, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Nanyang Medical College
        • Ta kontakt med:
          • Ou Zhang
      • Qingdao, Kina
        • Har ikke rekruttert ennå
        • The Affiliated Hospital of Qingdao University
        • Ta kontakt med:
          • Zhexun Lian
      • Qiqihar, Kina
        • Har ikke rekruttert ennå
        • Qiqihar First Hospital
        • Ta kontakt med:
          • Jinhui Zhang
      • Qiqihar, Kina
        • Har ikke rekruttert ennå
        • The Second Affiliated Hospital of Qiqihar Medical University
        • Ta kontakt med:
          • Xiaojie Wu
      • Qiqihar, Kina
        • Har ikke rekruttert ennå
        • The Third Affiliated Hospital of Qiqihar Medical University
        • Ta kontakt med:
          • Haifeng Shao
      • Shenyang, Kina
        • Har ikke rekruttert ennå
        • Shengjing Hospital of China Medical University
        • Ta kontakt med:
          • Zhijun Sun
      • Shenyang, Kina
        • Har ikke rekruttert ennå
        • The Fourth Affiliated Hospital of China Medical University
        • Ta kontakt med:
          • Yuanzhe Jin
      • Shenyang, Kina
        • Har ikke rekruttert ennå
        • Liaoning Provincial People's Hospital
        • Ta kontakt med:
          • Bo Luan
      • Shijia Zhuang, Kina
        • Har ikke rekruttert ennå
        • The Second Hospital of Hebei Medical University
        • Ta kontakt med:
          • Xinshun Gu
      • Shijiazhuang, Kina
        • Har ikke rekruttert ennå
        • Hebei Provincial People's Hospital
        • Ta kontakt med:
          • Yi Dang
      • Suihua, Kina
        • Har ikke rekruttert ennå
        • Suihua First Hospital
        • Ta kontakt med:
          • Qiuye Yang
      • Taiyuan, Kina
        • Har ikke rekruttert ennå
        • General Hospital of Taiyuan Iron and Steel (Group) Co.
        • Ta kontakt med:
          • Huifeng Wang
      • Taiyuan, Kina
        • Har ikke rekruttert ennå
        • Shanxi Provincial Cardiovascular Hospital
        • Ta kontakt med:
          • Zhulin Zhang
      • Tianjin, Kina
        • Har ikke rekruttert ennå
        • Tianjin Chest Hospital
        • Ta kontakt med:
          • Chunjie Li
      • Tianjin, Kina
        • Har ikke rekruttert ennå
        • Teda International Cardiovascular Hospital
        • Ta kontakt med:
          • Wenhua Lin
      • Tianjin, Kina
        • Har ikke rekruttert ennå
        • General Hospital of Tianjin Medical University
        • Ta kontakt med:
          • Qing Yang
      • Wenzhou, Kina
        • Har ikke rekruttert ennå
        • The Second Affiliated Hospital of Wenzhou Medical University
        • Ta kontakt med:
          • Xueqiang Guan
      • Wuhan, Kina
        • Har ikke rekruttert ennå
        • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
        • Ta kontakt med:
          • Xiang Cheng
      • Wuhan, Kina
        • Har ikke rekruttert ennå
        • Wuhan Asia Heart Hospital
        • Ta kontakt med:
          • Hua Yan
      • Xi'an, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Xi'an Jiaotong University
        • Ta kontakt med:
          • Zuyi Yuan
      • Xinjiang, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Xinjiang Medical University
        • Ta kontakt med:
          • Xiang Ma
      • Xinjiang, Kina
        • Har ikke rekruttert ennå
        • People's Hospital of Xinjiang Uygur Autonomous Region
        • Ta kontakt med:
          • Yining Yang
      • Yantai, Kina
        • Har ikke rekruttert ennå
        • Yantai YuHuangDing Hospital
        • Ta kontakt med:
          • Faxin Ren
      • Zhengzhou, Kina
        • Har ikke rekruttert ennå
        • The First Affiliated Hospital of Zhengzhou University
        • Ta kontakt med:
          • Jinying Zhang
      • Zhengzhou, Kina
        • Har ikke rekruttert ennå
        • Fuwai Huazhong Cardiovascular Hospital
        • Ta kontakt med:
          • Chuanyu Gao
      • Zunyi, Kina
        • Har ikke rekruttert ennå
        • Zunyi Medical University Affiliated Hospital
        • Ta kontakt med:
          • Ranzun Zhao
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150086
        • Rekruttering
        • The Second Affiliated Hospital of Harbin Medical University
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Beskrivelse

Inclusion Criteria:

  1. Male or female patients aged ≥18 years and ≤75 years;
  2. Diagnosis of type 1 AMI, including STEMI (onset <24 hours or 7-14 days) or NSTEMI;
  3. After coronary angiography (CAG) ± thrombus aspiration, TIMI flow in the culprit vessel is restored to grade 3 and maintained for at least 5 minutes, with diameter stenosis (DS) <70% at the culprit lesion (QCA);
  4. Reference diameter of the culprit lesion >2.5 mm and ≤4.0 mm;
  5. Patients or a legally authorized representative must provide written Informed Consent prior to any study related procedure.

Exclusion Criteria:

1.Clinical exclusion criteria:

  1. Severe cardiac dysfunction (Killip/NYHA class ≥ 3) or LVEF < 30%;
  2. Cardiopulmonary resuscitation (CPR) performed at the onset of AMI;
  3. Persistent hemodynamic or cardiac electrical instability after TIMI flow restoration;
  4. Contraindication to antithrombotic drugs, or concurrent hemorrhagic diseases such as peptic ulcer or coagulation disorders;
  5. Contraindication to contrast;
  6. Severe renal dysfunction [defined as eGFR ≤30 ml/min/1.73m² or Scr ≥2.0 mg/dL] without regular dialysis (patients with chronic renal insufficiency on regular dialysis may be considered for enrollment);
  7. Active liver disease, defined as known infectious, neoplastic, or metabolic liver lesions, with ALT and AST >3× upper limit of normal (ULN);
  8. Previous history of CABG or PCI for the culprit lesion;
  9. Patients with other concurrent severe diseases and an expected life expectancy of <1 year;
  10. Pregnant or lactating women. Women of childbearing potential must use effective contraceptive measures during the study treatment period;
  11. Inability to comply with the study protocol or other conditions deemed unsuitable for study participation by the investigator.

2.Imaging exclusion criteria:

  1. Non-culprit lesion with DS ≥70% or planned revascularization;
  2. Left main coronary artery lesion with DS ≥50%;
  3. Culprit lesion is a true bifurcation lesion requiring a two-stent strategy;
  4. Long lesion (planned stent length >60 mm);
  5. Culprit lesion with dissection, false lumen, or other conditions necessitating stent implantation;
  6. Target lesion has undergone pre-treatment (such as balloon dilation, rotational atherectomy, etc.).

3.Functional sub study:

  1. Individuals who are allergic to adenosine triphosphate (ATP) or any component in its preparations;
  2. Second and third degree atrioventricular block, sick sinus syndrome (without artificial pacemaker protectors);
  3. Patients with bronchial asthma.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Guideline-recommended standard medical therapy alone
Dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.
Legemiddel: Guideline-recommended standard medical therapy alone
Dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction
Aktiv komparator: DES implantation plus guideline-recommended standard medical therapy
DES implantation plus dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.
Fremgangsmåte: DES implantation plus guideline-recommended standard medical therapy
DES implantation plus dual antiplatelet therapy, anticoagulation, thrombolysis, lipid-lowering, and other guideline recommended drugs related to myocardial infarction.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Target Lesion Failure(TLF)
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
TLF is defined as a composite endpoint consisting of cardiovascular death, target vessel myocardial infarction and ischemia-driven target lesion revascularization.
From randomization to the end of the study, median follow-up duration is 30 months.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
All-cause death
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Cardiovascular death
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Myocardial infarction (MI)
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Target vessel myocardial infarction
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Coronary Revascularization
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Target vessel revascularization
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Target lesion revascularization
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Ischemia-driven target lesion revascularization
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Stroke
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Rehospitalization for unstable angina pectoris
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Rehospitalization for heart failure
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
From randomization to the end of the study, median follow-up duration is 30 months.
Major adverse cardiovascular and cerebrovascular events (MACCE)
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
MACCE: defined as a composite endpoint consisting of all-cause death, myocardial infarction, stroke, and repeat revascularization.
From randomization to the end of the study, median follow-up duration is 30 months.
Seattle Angina Questionnaire(SAQ)score
Tidsramme: From 24 hours after surgery to discharge and the 12th month after discharge
From 24 hours after surgery to discharge and the 12th month after discharge

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Definite or probable in-stent thrombosis
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
Safety endpoint
From randomization to the end of the study, median follow-up duration is 30 months.
Contrast-induced acute kidney injury(CI-AKI)
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
Safety endpoint
From randomization to the end of the study, median follow-up duration is 30 months.
Procedure-related myocardial infarction
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
Safety endpoint
From randomization to the end of the study, median follow-up duration is 30 months.
Bleeding Academic Research Consortium(BARC)type 3 and type 5 bleeding
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
Safety endpoint
From randomization to the end of the study, median follow-up duration is 30 months.
Microcirculation resistance index(IMR)to assess the incidence of coronary microvascular dysfunction (CMD)
Tidsramme: From randomization to the end of the study, median follow-up duration is 30 months.
Exploratory endpoint:Functional sub research
From randomization to the end of the study, median follow-up duration is 30 months.
The first occurrence of all-cause death and readmission due to heart failure within 12 months.
Tidsramme: From randomization to the 12th month.
Exploratory endpoint:Functional sub research
From randomization to the 12th month.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Harbin Medical University

Etterforskere

  • Hovedetterforsker: Bo Yu, Ph.D., The Second Affiliated Hospital of Harbin Medical University
  • Hovedetterforsker: Jingbo Hou, Ph.D., The Second Affiliated Hospital of Harbin Medical University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. juli 2026

Primær fullføring (Antatt)

1. april 2029

Studiet fullført (Antatt)

1. desember 2030

Datoer for studieregistrering

Først innsendt

21. april 2026

Først innsendt som oppfylte QC-kriteriene

30. april 2026

Først lagt ut (Faktiske)

5. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

16. juli 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. juli 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • KY2026-042

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere